← Leaderboards
William J Mc Cune
University Of Michigan At Ann Arbor
$1,023,853
Attributed
$1,884,594
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $773.3K · FY2005–14$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$1,884,594 · 8
By mechanism
R01$1,721,483 · 1
M01$163,111 · 7
Top collaborators
- Gregory M Christman3 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Erin Giles$1,967,139
- John G Weg$2,472,324
- Gregory M Christman$3,927,605
- Steven P. Schwendeman$6,555,011
- Samir M Hanash$22,144,784
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchWomanHuman SubjectMeasurementSystemic Lupus ErythematosusPharmaceutical PreparationsCardiovascular DiseasesPrevalenceVasculitisUltrasonographyDoseCyclophosphamideRandomizedPlacebosLupusFollow-UpInjuryAutoimmune DiseasesAffectDetectionComorbidityAgonistClinical TrialsAdverse Effects
Grant awards (17)
RCT of GnRH-a for ovarian protection during CYC therapy for rheumatic disease$1
R01 · FY2014 · HD · contact PI
RCT of GnRH-a for ovarian protection during CYC therapy for rheumatic disease$190,519
R01 · FY2012 · HD · contact PI
RCT of GnRH-a for ovarian protection during CYC therapy for rheumatic disease$757,630
R01 · FY2011 · HD · contact PI
RCT of GnRH-a for ovarian protection during CYC therapy for rheumatic disease$773,333
R01 · FY2010 · HD · contact PI
ENDOTHELIAL DYSFUNCTION IN CHILDREN & ADULTS W/ SYSTEMIC LUPUS ERYTHEMATOSUS$9,037
M01 · FY2007 · RR · contact PI
EFFICACY & SAFETY OF RITUXIMAB FOR MOD TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS$227
M01 · FY2007 · RR · contact PI
ENDOTHELIAL DYSFUNCTION IN CHILDREN & ADULTS W/ SYSTEMIC LUPUS ERYTHEMATOSUS$37,812
M01 · FY2006 · RR · contact PI
DOES DHEA IMPROVE ENDOTHELIAL DYSFUNCTION IN SLE?$14,307
M01 · FY2006 · RR · contact PI
ENDOTHELIAL DYSFUNCTION IN CHILDREN &ADULTS W/ SYSTEMIC LUPUS ERYTHEMATOSUS$29,849
M01 · FY2005 · RR
DOES DHEA IMPROVE ENDOTHELIAL DYSFUNCTION IN SLE?$14,409
M01 · FY2005 · RR
TREATMENT WITH ETANERCEPT FOR WEGENER'S GRANULOMATOSIS$2,574
M01 · FY2005 · RR
Endothelial Dysfunction in Children &Adults w/ Systemic Lupus Erythematosus$38,122
M01 · FY2004 · RR
Treatment with Etanercept for Wegener's Granulomatosis$10,166
M01 · FY2004 · RR
Does DHEA Improve Endothelial Dysfunction in SLE?$6,100
M01 · FY2004 · RR
Mycophenolate Mofetil vs. Placebo in Pts w/ Systemic Lupus Erythematosus$508
M01 · FY2004 · RR
Safety of estrogens in lupus erythematosus national assessment$0
M01 · FY2002 · RR
Safety of estrogens in lupus erythematosus national assessment$0
M01 · FY2000 · RR